Anti-vascular endothelial growth factor (anti-VEGF) agents have become the first-line therapy for various eye diseases including age-related macular degeneration (AMD) [1, 2], retinal vein occlusion related macular edema (RVO-ME) [3], and diabetic macular edema (DME) [4]. This evidence concerns the gene VEGFA and age-related macular degeneration.